Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03946150

PaO2/FiO2*PEEP (P/FP) Ratio and Mortality in Acute Respiratory Distress Syndrome.

Adult Respiratory Distress Syndrome Clinical Trial

Official title:
PaO2/FiO2*PEEP (P/FP) Ratio and Mortality in Acute Respiratory Distress Syndrome

Clinical Trial Summary

The PaO2/FiO2 (P/F) ratio is same for all the Positive End Expiratory Pressure (PEEP) ≥ to 5. This P/F ratio misleads the severity of disease without the knowledge of set PEEP. The Oxygenation status is actually worse when the patient is using high PEEP.

P/F Ratio doesn't include PEEP in the calculation.The P/F ratio doesn't show the severity of the disease appropriate for the set PEEP.

PaO2/(FiO2 X PEEP) P/FP Ratio is a new Formula which addresses this gap to appropriately calculate the severity of the disease by including PEEP in the formula.

This formula is used to predict mortality for different severities of ARDS.

Clinical Trial Description

The Main aim of this study is to analyse whether this formula can early diagnose the severity of the disease appropriate for the set PEEP, so the Rescue measure can be started early which can eventually decreases the mortality.

Increasing the PEEP Value with the same Fio2 gives a different PaO2 and SpO2. The oxygenation improves substantially by increasing only the PEEP. So including the PEEP in calculating the severity of Oxygenation is better than the current practice.

The current Definition of ARDS for Oxygenation is P/F Ratio of 300 to 200 is Mild, 200 to 100 is Moderate and less than 100 is Severe ARDS with PEEP ≥ 5.

The New P/FP Ratio of 300 to 200 is mild, 200 to 100 is moderate and less than 100 is severe Adult Respiratory Distress Syndrome (ARDS) for all the different levels of PEEP values. ;

Study Design

Related Conditions & MeSH terms

  • Acute Lung Injury
  • Adult Respiratory Distress Syndrome
  • Respiratory Distress Syndrome, Adult
  • Respiratory Distress Syndrome, Newborn
  • Syndrome
Clinical Trial Details
NCT number NCT03946150
Study type Observational
Source National University Health System, Singapore
Contact
Status Completed
Phase
Start date June 1, 2017
Completion date March 3, 2020
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01722422 - Hyperoxia and Hypertonic Saline in Septic Shock N/A
Withdrawn NCT01195428 - Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS) N/A
Terminated NCT01901354 - Acute Lung Injury Ventilator Evaluation (ALIVE) N/A
Withdrawn NCT00793013 - Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation Phase 2
Terminated NCT01667666 - Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury Phase 1
Completed NCT00314548 - Inhaled Prostacyclin for Adult Respiratory Distress Syndrome (ARDS) and Pulmonary Hypertension N/A
Completed NCT04390139 - Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 Phase 1/Phase 2
Withdrawn NCT01083355 - Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury (ALI) N/A
Terminated NCT04778059 - Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19 Phase 2
Terminated NCT01038531 - Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation N/A
Recruiting NCT04079426 - Tetracycline to Limit the Innate Immune Response in Acute Respiratory Distress Syndrome
Terminated NCT01769053 - Variable Pressure Support Trial N/A
Completed NCT02804945 - Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies Phase 1
Completed NCT00155779 - ACE Gene Polymorphism and ARDS Outcome N/A
Completed NCT00465309 - Protective Ventilation With Carbon Dioxide (CO2) -Removal Technique in Patients With Adult Respiratory Distress Syndrome (ARDS) Phase 3